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OBJECTIVES We examined the utility of early percutaneous coronary intervention (PCI) in a trial that
encouraged its use after thrombolysis and glycoprotein IIb/IIIa inhibition for acute myocar-
dial infarction (MI).
BACKGROUND Early PCI has shown no benefit when performed early after thrombolysis alone.
METHODS We studied 323 patients (61%) who underwent PCI with planned initial angiography, at a
median 63 min after reperfusion therapy began. A blinded core laboratory reviewed
cineangiograms. Ischemic events, bleeding, angiographic results, and clinical outcomes were
compared between early PCI and no-PCI patients (n 5 162), between patients with
Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 or 1 before PCI versus flow
grade 2 or 3, and among three treatment regimens.
RESULTS Early PCI patients showed a procedural success (,50% residual stenosis and TIMI flow grade 3)
rate of 88% and a 30-day composite incidence of death, reinfarction, or urgent revascularization
of 5.6%. These patients had fewer ischemic events and bleeding complications (15%) than did
patients not undergoing early PCI (30%, p 5 0.001). Early PCI was used more often in patients
with initial TIMI flow grade 0 or 1 versus flow grade 2 or 3 (83% vs. 60%, p , 0.0001). Patients
receiving abciximab with reduced-dose reteplase (5 U double bolus) showed an 86% incidence of
TIMI grade 3 flow at ;90 min and a trend toward improved outcomes.
CONCLUSIONS In this analysis, early PCI facilitated by a combination of abciximab and reduced-dose
reteplase was safe and effective. This approach has several advantages for acute MI patients,
which should be confirmed in a dedicated, randomized trial. (J Am Coll Cardiol 2000;36:
1489–96) © 2000 by the American College of Cardiology
Percutaneous coronary intervention (PCI) often is per-
formed in patients with acute myocardial infarction (MI),
but controversy exists about the optimal indications and
timing (1). In patients first treated with thrombolysis,
immediate angioplasty has not been shown to provide any
See page 1497
advantage over performing the procedure 18 to 48 h later (2)
or 7 to 10 days later (3) or compared with a conservative
strategy requiring noninvasive testing before angioplasty
(4,5). Angioplasty techniques have advanced substantially
since these trials, however, and they include the current
widespread use of stents and potent antiplatelet therapies.
The recent Strategies for Patency Enhancement in the
Emergency Department (SPEED, or the Global Use of
Strategies To Open Occluded coronary arteries [GUSTO-
4] Pilot) trial, a randomized study of abciximab with or
without low-dose fibrinolytic therapy for acute MI, showed
improved patency of the infarct-related artery at 60 to
90 min, compared with a standard lytic regimen (6).
Because all patients in this trial had early angiography and
PCI was encouraged, there is an opportunity to re-examine
the utility of early PCI after thrombolysis in a contemporary
setting. We used the term facilitated PCI to describe early,
planned PCI after a pharmacological regimen intended to
open the infarct-related artery. Our hypothesis was that
facilitated PCI incorporating stents and platelet glycopro-
tein IIb/IIIa therapy would be safe and would improve the
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angiographic and procedural outcomes of patients with
acute MI.
METHODS
Study population. The trial enrolled 528 patients with
ST-segment elevation acute MI within 6 h of chest-pain
onset (6). Patients with pulmonary edema or shock, previ-
ous bypass surgery or stroke, severe hypertension, or con-
traindication to thrombolysis were excluded. In the initial
dose-ranging phase of the trial, 304 patients were random-
ized in a 4:1 ratio to receive abciximab (0.25-mg/kg bolus
and 12-h infusion at 0.125 mg/kg/min) with reteplase (5 U,
7.5 U, 10 U, 5 1 2.5 U, or 5 1 5 U boluses) or no reteplase.
The two reteplase boluses were given 30 min apart. All
patients received aspirin and intravenous heparin as a
weight-adjusted bolus (60 U/kg) and additional boluses to
achieve an activated clotting time $200 s.
In the second, dose-confirmation phase of the trial, 223
patients were randomized to receive full-dose reteplase
(10 1 10 U) or the Phase 1 regimen that resulted in the
highest rate of Thrombolysis In Myocardial Infarction
(TIMI) grade 3 flow before PCI—abciximab with reduced-
dose reteplase (5 1 5 U). In this phase, heparin was
administered as 40 U/kg (maximum 4,000 U) in the
combination arm and 70 U/kg in full-dose reteplase pa-
tients. The primary end point in both phases was the
incidence of TIMI grade 3 flow in the infarct-related artery
(7) at angiography 60 min to 90 min after treatment began,
as assessed by the core laboratory.
Cardiac catheterization and intervention. Coronary an-
giography was performed as soon as possible after reperfu-
sion therapy began; then PCI was performed at the inves-
tigator’s discretion using any approved techniques and
devices. “Early” intervention was defined as PCI performed
at the time of first angiography. Based on the median
angiography time of 63 min, balloon inflation was estimated
to have occurred by 90 min. All cineangiograms were
reviewed in a blinded manner by the angiographic core
laboratory (Cleveland Clinic Foundation). Angiographic
variables collected before and after PCI included percent
diameter stenosis, TIMI flow grade, corrected TIMI frame
count (CTFC) (8), and the presence of distal embolization,
no-reflow, dissection, or perforation.
Procedural success was defined as post-PCI residual
stenosis #50% with TIMI grade 3 flow. Major outcomes
included death, reinfarction, or urgent, repeat PCI or bypass
surgery for ischemia. Bleeding complications within 14 days
were categorized as major (any intracranial, retroperitoneal,
or intraocular bleeding, or a decrease in hemoglobin
.5 g/dl), intracranial hemorrhage, or requiring transfusion.
A composite “clinical success” variable was defined as
freedom from death, reinfarction, urgent revascularization,
major bleeding, or transfusion at 30 days.
Statistical analysis. Categorical variables were summarized
as frequencies with percentages, and continuous variables as
means 6 SD or medians with interquartile ranges. We
compared patients who did and did not undergo early
intervention by use of the Fisher exact test for discrete
variables and the Wilcoxon rank-sum test for continuous
variables. Within the cohort of patients receiving early PCI,
those with TIMI flow grade 0 or 1 before PCI were
compared with those with TIMI flow grade 2 or 3 before
PCI. Finally, we used log likelihood chi-square and the
Kruskal-Wallis test to compare early PCI data from the
dose-finding and dose-confirmation phases for three treat-
ment regimens: abciximab alone, full-dose reteplase alone,
and abciximab with reteplase 5 1 5 U.
RESULTS
Angiography was performed within the intended 60-to-90-
min period in 466 of the 528 patients (median, 63 min;
interquartile range, 60 min to 70 min). Investigators re-
ported that PCI was performed with first angiography in
323 patients (61% of the intention-to-treat cohort), which
made up the facilitated-PCI study population. Of the 205
patients who did not have early PCI, 43 had PCI with an
initial angiogram performed either before or after the
qualifying 60-to-90-min period or were missing TIMI
grade flow and were excluded from analysis. The remaining
162 patients formed the “no early PCI” comparison group.
Overall results of early PCI. In the early-PCI group, the
site-reported procedural success rate was 88%, and 78%
received intracoronary stents. The mean age of patients was
60 6 12 years, and 75% were men (Table 1). Diabetes and
hypertension were present in 18% and 33%, respectively.
The right coronary was the most prevalent infarct-related
artery. Major outcomes occurred in 5.6% of patients, which
included death (3.4%), reinfarction (1.2%), and urgent
revascularization for severe ischemia (1.6%). Within 14
days, 6.5% of this group had major bleeding, and 9.0%
required blood transfusion. Other procedure-related com-
plications are shown in Table 2.
The 162 patients who did not undergo early PCI did not
differ significantly in clinical characteristics or infarct loca-
tion from the early-PCI group, but their rates of reinfarc-
tion (4.9%), urgent revascularization (9.3%), the composite
Abbreviations and Acronyms
CTFC 5 corrected TIMI frame count
GUSTO-I 5 Global Utilization of Streptokinase
and TPA (alteplase) for Occluded
Coronary Arteries
GUSTO-III, 24 5 Global Use of Strategies To Open
Occluded coronary arteries
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
SPEED 5 Strategies for Patency Enhancement
in the Emergency Department
TIMI 5 Thrombolysis In Myocardial Infarc-
tion
1490 Herrmann et al. JACC Vol. 36, No. 5, 2000
Facilitated PCI After Myocardial Infarction November 1, 2000:1489–96
of major outcomes (16.0%), and transfusion (16.0%) were
substantially higher (Table 1; Fig. 1). The clinical success
rate was 85.4% for early-PCI patients and 70.4% for those
not undergoing early PCI (p , 0.001) (Fig. 2).
The TIMI flow grade before and after PCI was assessed
by the core laboratory in 294 patients with evaluable
angiograms. Before PCI, 99 patients (33.7%) had TIMI
flow grade 0 or 1, and 195 patients (66.3%) had TIMI flow
grade 2 or 3. The no-early-PCI patients were more likely to
have patent arteries on the 60-to-90-min angiogram (TIMI
flow grade 2 or 3 5 91%) than early-PCI patients (p ,
0.001). After early PCI, the percentage of patients with
TIMI flow grade 2 or 3 improved to 97.6% (p , 0.001)
(Fig. 3).
Results by initial TIMI flow grade. Despite the absence
of differences in baseline characteristics other than the
difference in TIMI flow, patients with TIMI flow grade 0 or
1 before PCI (n 5 99) underwent early PCI more often
(83% vs. 60%, p , 0.0001), but they were less likely to have
TIMI grade 3 flow or a normal corrected TIMI frame count
after PCI (Table 2). There were no significant differences in
30-day clinical outcomes or bleeding complications.
Comparison by treatment assignment. By intention-to-
treat, 63 patients were randomized to abciximab alone, 109
patients to full-dose reteplase alone (two 10 U boluses,
30 min apart), and 191 patients to abciximab and reteplase
(two 5 U boluses, 30 min apart). Of these, 294 patients
(81%) had evaluable angiograms, and 195 (66%) underwent
early PCI.
Early PCI was performed more often in patients receiving
abciximab alone, probably reflecting the lower initial rate of
TIMI grade 3 flow. Stents were used most often in the
full-dose reteplase group. After PCI, TIMI grade 3 flow
was present in 84% to 95% of patients. In patients receiving
combination therapy, which resulted in the highest rate of
TIMI grade 3 flow (47%) at 60 to 65 min, post-PCI TIMI
grade 3 flow was present in 86% at an estimated 90 min after
treatment began.
Corrected TIMI frame count analysis confirmed the
TIMI flow-grade data, with the lowest counts before PCI in
patients receiving combination therapy. After early PCI, the
mean CTFC was normal (,30) in all three treatment
groups.
There was a trend toward improved 30-day outcomes in
the patients receiving combination therapy, with a rate of
death, MI, and urgent revascularization of 5.9%, compared
with 8.1% and 7.1% in patients receiving abciximab or
reteplase alone, respectively. Intracranial hemorrhage was
rare in all three groups; however, a trend was apparent
toward greater bleeding complications primarily at vascular
access sites with combination therapy. Clinical success at 30
days was similar (85% to 89%) for all treatment regimens
(Table 3).
DISCUSSION
The SPEED (GUSTO-4 Pilot) trial showed that the
combination strategy of potent platelet inhibition (abcix-
imab) and reduced-dose thrombolysis (reteplase) improves
infarct-related artery patency at 60 to 90 min, compared
with abciximab alone or full-dose reteplase (6). Unlike the
TIMI-14 trial (9), which reached a similar conclusion using
alteplase, intervention at the time of initial angiography was
encouraged in SPEED, resulting in early PCI in 61% of
enrolled patients.
Results of early PCI. The results of PCI in this setting
appear to be both safe and effective. Procedural success was
achieved in 88% of patients, with a 30-day composite rate of
death, reinfarction, and urgent revascularization of 5.6%.
Overall clinical success at 30 days—freedom from death,
reinfarction, urgent revascularization, major bleeding, and
transfusion—was achieved in 85% of patients undergoing
early PCI. These results contrast with previous studies of
angioplasty performed shortly after full-dose thrombolysis
(2–5). Although these earlier trials varied in the thrombo-
lytic agent used, the timing of intervention, and the out-
come measured, their results were surprisingly similar. In all
four trials, immediate angioplasty had a lower success rate,
higher mortality, and higher rates of reinfarction, bypass
surgery, and transfusion than did delayed intervention or a
conservative approach (2–5).
The most likely reasons for the better results in the
present trial include the use of abciximab, intracoronary
Table 1. Characteristics and Outcomes by Performance of Early
Percutaneous Coronary Intervention (PCI)
Early PCI
(n 5 323)
No Early PCI
(n 5 162)
p
Value
Clinical characteristics
Age (yrs) 60 6 12 59 6 12 0.87
Male gender 242 (74.9%) 117 (72.2%) 0.58
Diabetes mellitus 58 (18.0%) 29 (17.9%) 1.00
Hypertension 107 (33.1%) 50 (30.9%) 0.68
Angiographic
characteristics
Infarct location 0.92
Anterior 128 (40.1%) 60 (39.2%)
Inferior 191 (59.9%) 93 (60.8%)
Infarct artery 0.001
Left anterior
descending
117 (36.3%) 50 (34.0%)
Left circumflex 30 (9.3%) 30 (20.4%)
Right coronary 174 (54.0%) 56 (38.1%)
Major outcomes
Death 11 (3.4%) 6 (3.7%) 1.00
Reinfarction 4 (1.2%) 8 (4.9%) 0.03
Urgent revascularization
for ischemia
5 (1.6%) 15 (9.3%) 0.001
Composite 18 (5.6%) 26 (16.0%) 0.001
Death or reinfarction 14 (4.3%) 13 (8.0%) 0.14
Bleeding events
Major bleeding 21 (6.5%) 14 (8.6%) 0.46
Intracranial hemorrhage 2 (0.6%) 0 (0%) 0.55
Transfusion 29 (9.0%) 26 (16.0%) 0.02
Clinical success 276 (85.4%) 114 (70.4%) 0.001
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stents, optimization of heparin anticoagulation, and in-
creased operator experience. Although one recent trial
utilizing a reduced dose lytic with early planned PCI
demonstrated no increase in the acute frequency of adverse
events—despite a low usage of stents (26%) and abciximab
(5%) (10)—platelet activation is an important contributing
factor in thrombus formation after thrombolysis for acute
MI (11). In this regard, several trials have shown that
abciximab can improve the results of primary angioplasty in
acute MI. In the ReoPro and Primary PTCA Organization
and Randomized Trial (RAPPORT), 483 patients with
acute MI were randomized to abciximab or placebo before
angioplasty (12). The rates of death or MI and death, MI,
or urgent revascularization were reduced from 11.2% to
8.7% and from 17.8% to 11.8%, respectively (12). A similar
47% reduction in a combined end point was observed in the
ADMIRAL (Abciximab before Direct angioplasty and
stenting in acute Myocardial Infarction Regarding Acute
and Long-term follow-up) trial, which also allowed stent
implantation (13). The benefit of stenting in acute MI also
has been examined without abciximab and shown to be safe
and to improve short-term outcomes (14,15). Other studies
are under way that will address various combinations of
abciximab, primary angioplasty, and primary stenting (16).
The specific fibrinolytic agent used, reteplase in this case,
also may have contributed to the improved outcome. Rete-
plase has been shown to produce greater early TIMI grade
3 flow compared with alteplase (17). Although the
GUSTO-III trial showed no difference in mortality rates of
patients with MI treated with reteplase versus alteplase (18),
patients undergoing rescue angioplasty with abciximab had
improved outcomes when they had been randomized to
reteplase compared with alteplase (19).
Benefits of facilitated PCI. Our data suggest multiple
benefits from the use of combination therapy with abcix-
imab and reduced-dose thrombolysis for “facilitated early
PCI,” a term we propose to refer to planned PCI after
pharmacological reperfusion therapy. Facilitated early PCI
must be differentiated from direct or primary PCI (without
thrombolysis); from immediate, early, or delayed PCI after
full-dose thrombolytic administration; from rescue PCI
after thrombolysis, with or without platelet glycoprotein
IIb/IIIa inhibition; and from primary PCI with a glyco-
protein IIb/IIIa inhibitor alone, either before or during PCI.
Table 2. Characteristics and Outcomes Among Patients Undergoing Early Percutaneous
Coronary Intervention (PCI), by Initial TIMI Flow Grade*
All Patients
(n 5 294)
Flow Grade 0 or 1
(n 5 99)
Flow Grade 2 or 3
(n 5 195) p Value
Early PCI 66% 83% 60% 0.0001
Baseline characteristics
Age (yrs) 60 6 12 59 6 12 61 6 12 0.22
Male gender 221 (75.2%) 76 (76.8%) 145 (74.4%) 0.67
Diabetes mellitus 52 (17.7%) 22 (22.2%) 30 (15.4%) 0.15
Hypertension 101 (34.4%) 37 (37.4%) 64 (32.8%) 0.44
Angiographic characteristics
Infarct-related artery 0.22
Left anterior descending 106 (36.2%) 29 (29.6%) 76 (39.5%)
Left circumflex 23 (7.9%) 7 (7.1%) 16 (8.2%)
Right coronary 164 (56.0%) 62 (63.3%) 102 (52.3%)
Stent 235 (79.9%) 73 (73.7%) 162 (83.1%) 0.07
Post-PCI TIMI grade 3 flow 251 (85.4%) 76 (76.8%) 175 (89.7%) 0.001
CTFC before PCI 62 6 35 100 6 0 39 6 25 0.0001
CTFC after PCI 26 6 19 33 6 27 23 6 13 0.02
Normal CTFC after PCI 171 (72.8%) 50 (63.3%) 121 (77.6%) 0.03
Pre-PCI percent stenosis 81 6 15 98 6 7 73 6 10 0.0001
Post-PCI percent stenosis 26 6 17 31 6 21 23 6 14 0.004
Complications 70 (26.9%) 27 (32.9%) 43 (24.2%) 0.18
Abrupt closure 25 (8.5%) 9 (9.1%) 16 (8.2%) 0.83
Distal embolization 33 (12.7%) 14 (17.1%) 19 (10.7%) 0.16
Perforation 1 (0.3%) 0 1 (0.5%) 1.00
Dissection 29 (10.0%) 10 (10.4%) 19 (9.7%) 0.84
Major outcomes
Death 10 (3.4%) 3 (3.0%) 7 (3.6%) 1.00
Reinfarction 4 (1.4%) 3 (3.0%) 1 (0.5%) 0.11
Urgent revascularization 4 (1.4%) 2 (2.0%) 2 (1.0%) 0.61
Composite 16 (5.4%) 7 (7.1%) 9 (4.6%) 0.42
Death or reinfarction 13 (4.4%) 5 (5.1%) 8 (4.1%) 0.77
Bleeding complications
Major bleeding 20 (6.8%) 6 (6.1%) 14 (7.2%) 0.81
Transfusion 26 (8.8%) 6 (6.1%) 20 (10.3%) 0.28
Clinical success 251 (85.4%) 85 (85.9%) 166 (85.1%) 1.00
*Patients with evaluable angiograms. CTFC 5 corrected TIMI frame count; TIMI 5 Thrombolysis In Myocardial Infarction.
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Early PCI was performed less often in patients receiving
combination therapy (65% vs. 82% in patients receiving
abciximab alone), which probably reflects the improved flow
achieved before PCI in these patients. Early PCI was also
performed less often in patients with improved flow (Table
2), and combination-therapy patients were more likely to
have a patent artery at initial angiography. The possibility
that an improved combination pharmacological regimen
could lessen the need for early PCI suggests that this
strategy might be cost-effective. In this regard, patients
undergoing early PCI also had less major bleeding and
required fewer transfusions by 30 days, probably reflecting
the less frequent need for urgent revascularization including
coronary artery bypass graft surgery.
Another advantage of facilitated early PCI relates to
patient stability in the catheterization laboratory. Patients
arriving in the laboratory with patent infarct-related arteries
due to earlier reperfusion are less likely to be in cardiogenic
shock, to require an intra-aortic balloon pump or temporary
pacemaker, or to suffer cardiac arrest (20). Furthermore, a
less hectic procedure and the ability to visualize the distal
vessel may improve the technical success of angioplasty.
Finally, facilitated early PCI has the potential to fuse the
best aspects of thrombolysis and primary angioplasty in the
management of acute MI. A long-standing controversy has
focused on which strategy provides the best outcome based
on the incidence of TIMI grade 3 flow at 90 min (21–23).
The time at which normal flow is achieved is equally
important, however (24). A combined pharmacological
approach using abciximab and reduced-dose reteplase or
alteplase can improve TIMI grade 3 flow rates at 60 min by
an absolute 10% to 15% (6–9). Primary angioplasty can
achieve higher TIMI grade 3 flow rates than thrombolysis,
but generally at later time points (23–25). The addition of
early facilitated PCI in this trial between 60 and 90 min
resulted in an extremely high core-laboratory-assessed
TIMI grade 3 flow rate (85%) and a normal mean corrected
TIMI frame count, without sacrificing the early benefit
(between 30 and 60 min) of a pharmacological approach.
We believe that the additive benefits of these two ap-
proaches could provide the optimal reperfusion strategy for
many patients with acute MI (Fig. 4).
Study limitations. Early PCI was not mandated in this study
and was therefore applied at each investigator’s discretion. This
limits the comparison of early PCI patients with those not
receiving PCI, as well as between different treatments, when
the rate of early PCI varied. It is likely that physician selection
influenced the use of early PCI, and it is possible that
unmeasured, confounding variables contributed to the different
outcomes observed in these comparisons. However, this is the
largest study of this novel approach in a contemporary setting
using stents and core-laboratory analysis. Our study used
Figure 1. Major outcomes and bleeding complications in patients undergoing early PCI (n 5 323, black bars) compared with patients who did not undergo
early PCI (n 5 162, white bars). ReMI denotes reinfarction; revasc denotes revascularization. *p , 0.05.
Figure 2. The freedom from the composite of death, reinfarction, or
urgent revascularization for severe ischemia at 30 days is shown for patients
who did (top line) and did not (bottom line) undergo early PCI.
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TIMI grade 3 flow as a primary end point. Although the
Global Utilization of Streptokinase and TPA (alteplase) for
Occluded Coronary Arteries (GUSTO-I) trial (25) confirmed
a direct relation between TIMI grade 3 flow and survival, it is
unknown whether further improvements in TIMI flow will
result in greater survival (26). The recently reported discrep-
ancy between myocardial tissue perfusion and epicardial coro-
nary flow highlights this potential limitation of TIMI flow
grade as a surrogate end point (27).
Clinical implications. This study shows the safety and
efficacy of early PCI in acute MI, facilitated by a combination
of abciximab and reduced-dose reteplase. This approach has
the potential to improve both very early and later reperfusion
rates and to become the optimal reperfusion strategy. How-
ever, the mortality benefit and safety of combined therapy with
abciximab and a low-dose fibrinolytic must first be validated in
a large trial, such as the current GUSTO-4 acute MI trial, and
the benefits of facilitated PCI should be confirmed in a
dedicated, randomized trial.
Reprint requests and correspondence: Dr. Howard C. Herr-
mann, Hospital of the University of Pennsylvania, 3400 Spruce
Street, 9 Founders Pavilion, Philadelphia, Pennsylvania 19104.
Figure 3. Proportions of patients with TIMI flow grade (bars, left to right) 0, 1, 2, or 3, before and after early PCI.
Table 3. Characteristics and Outcomes Among Patients Undergoing Early Percutaneous
Coronary Intervention (PCI), by Treatment Assignment*
Abciximab Alone
(n 5 37)
Reteplase Alone
(n 5 56)
Abciximab/Reteplase
5 1 5 U (n 5 102)
p
Value†
Early PCI 82% 61% 65% 0.03
Stents 27 (73.0%) 51 (91.1%) 78 (76.5%) 0.03
Angiographic characteristics
Pre-PCI percent stenosis 87 6 15 80 6 17 79 6 14 0.06
Post-PCI percent stenosis 24 6 14 22 6 17 27 6 17 0.06
Pre-PCI TIMI grade 3 flow 9 (24.3%) 22 (39.3%) 48 (47.1%) 0.05
Post-PCI TIMI grade 3 flow 35 (94.6%) 46 (83.6%) 87 (86.1%) 0.23
CTFC before PCI 81 6 29 62 6 39 54 6 34 0.002
CTFC after PCI 26 6 22 26 6 20 26 6 19 0.78
Normal CTFC after PCI 24 (80.0%) 33 (73.3%) 60 (75.9%) 0.80
Angiograpic complications 8 (25.0%) 12 (24.5%) 27 (29.3%) 0.79
Major outcomes
Death, reinfarction, urgent
revascularization
3 (8.1%) 4 (7.1%) 6 (5.9%) 0.89
Death or reinfarction 2 (5.4%) 3 (5.4%) 6 (5.9%) 0.99
Bleeding complications
Major bleeding 1 (2.7%) 2 (3.6%) 9 (8.8%) 0.24
Transfusion 1 (2.7%) 4 (7.1%) 10 (9.8%) 0.31
Clinical success 33 (89.2%) 48 (85.7%) 87 (85.3%) 0.83
*Patients with evaluable angiograms. †Across three groups. Abbreviations as in Table 2.
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